Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease

Authors:
  • SSStefan Schreiber
    Stefan Schreiber
  • BJByung Ik Jang
    Byung Ik Jang
  • VBVladimir Borzan
    Vladimir Borzan
  • ALAdi Lahat
    Adi Lahat
  • APAldis Pukitis
    Aldis Pukitis
  • MOMarina Osipenko
    Marina Osipenko
  • YMYuriy Mostovoy
    Yuriy Mostovoy
  • SBShomron Ben-Horin
    Shomron Ben-Horin
  • BYByong Duk Ye
    Byong Duk Ye
  • SLSang Joon Lee
    Sang Joon Lee
  • SLSung Young Lee
    Sung Young Lee
  • MKMi Rim Kim
    Mi Rim Kim

Abstract
No abstract available